AMPA Receptor Protein

AMPA Receptor Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Protein</th>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">GluR1</td>
<td>GRIA1</td>
</tr>
<tr>
<td class="label">GluR2</td>
<td>GRIA2</td>
</tr>
<tr>
<td class="label">GluR3</td>
<td>GRIA3</td>
</tr>
<tr>
<td class="label">GluR4</td>
<td>GRIA4</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Ampa Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

AMPA Receptor Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Protein</th>
</tr>
<tr>
<td class="label">Subunit</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">GluR1</td>
<td>GRIA1</td>
</tr>
<tr>
<td class="label">GluR2</td>
<td>GRIA2</td>
</tr>
<tr>
<td class="label">GluR3</td>
<td>GRIA3</td>
</tr>
<tr>
<td class="label">GluR4</td>
<td>GRIA4</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Ampa Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

AMPA receptor subunits (also known as ionotropic glutamate receptor subunits or GluA1-4) are the fundamental building blocks of [α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors](/entities/ampa-receptors), which mediate the majority of fast excitatory synaptic transmission in the mammalian central nervous system. The four subunits—[GluR1](/genes/gria1) (GRIA1), [GluR2](/genes/gria2) (GRIA2), [GluR3](/genes/gria3) (GRIA3), and [GluR4](/genes/proteins/gria4) (GRIA4)—assemble to form functional ion channels that are critical for synaptic plasticity, learning, and memory. Dysfunction of AMPA receptor subunits has been implicated in numerous neurodegenerative and neuropsychiatric disorders including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), epilepsy, and schizophrenia.

Structure

AMPA receptor subunits are [ligand-gated ion channels](/entities/ion-channels) with a characteristic modular architecture:

• Extracellular N-terminal domain: Responsible for subunit assembly and receptor tetramerization
• Ligand-binding domain (LBD): Binds glutamate and allosteric modulators; contains the flip and flop splice variants that determine desensitization kinetics
• Transmembrane domain: Four hydrophobic segments (M1-M4) that form the ion channel pore
• C-terminal intracellular domain: Regulates trafficking, phosphorylation, and interaction with scaffolding proteins like [PSD-95](/entities/psd-95)

Subunit Composition

Normal Function

Fast Excitatory Synaptic Transmission

Synaptic Plasticity

• [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP): Activity-dependent strengthening of synapses, requiring [GluR1](/genes/gria1) subunit insertion
• Long-term depression (LTD): Activity-dependent weakening of synapses, requiring [GluR2](/genes/gria2) endocytosis
• Homeostatic plasticity: Scaling of synaptic strength in response to activity changes

Ion Permeability

• GluR2-containing receptors: Predominantly Na⁺ permeable, poorly permeable to Ca²⁺ due to Q/R site editing
• GluR2-lacking receptors (GluR1, GluR3, GluR4): Calcium-permeable, allowing Ca²⁺ influx that triggers intracellular signaling cascades

Role in Disease

Alzheimer's Disease

• Reduced [hippocampal](/brain-regions/hippocampus) expression of GluR1 and GluR2
• [Amyloid-beta](/proteins/amyloid-beta) oligomers impair AMPA receptor trafficking
• Decreased surface expression contributes to synaptic dysfunction
• Early marker of [synaptic](/mechanisms/synaptic-loss) vulnerability

Parkinson's Disease

• Altered striatal AMPA receptor composition
• Changes in GluR2 phosphorylation contribute to levodopa-induced dyskinesias
• [NMDA](/entities/nmda-receptors) receptor interactions are altered

Amyotrophic Lateral Sclerosis (ALS)

• Excitotoxicity via calcium-permeable AMPA receptors
• Reduced GluR2 expression in motor [neurons](/entities/neurons)
• [Riluzole](/therapeutics/riluzole) partially acts through AMPA receptor modulation

Epilepsy

• Mutations in GRIA2 and GRIA4 cause epileptic encephalopathy
• Aberrant trafficking contributes to hyperexcitability
• Q/R site editing efficiency affects calcium permeability

Schizophrenia

• GRIA3 and GRIA4 variants associated with disease risk
• Altered receptor trafficking in prefrontal [cortex](/brain-regions/cortex)
• Interaction with [NMDA receptor](/entities/nmda-receptor) dysfunction

Therapeutic Targeting

Positive Allosteric Modulators (Ampakines)

• CX516 (Ampalex): First-generation ampakine, cognitive enhancement
• CX717, CX1739: Advanced candidates in clinical trials
• LY404187: Preclinical cognitive enhancement

Negative Modulators

• Perampanel: FDA-approved [anticonvulsant](/therapeutics/anticonvulsants) for epilepsy
• Acts as a non-competitive antagonist

TARP Modulators

• Cyclothiazide: Blocks desensitization
• Stargazin: Model TARP for studying modulation

Gene Therapy

• AAV-mediated GRIA1/GRIA2 delivery for circuit repair
• Viral expression of edited GluR2 to reduce excitotoxicity

Animal Models

Knockout Studies

• GRIA1⁻/⁻: Impaired LTP, spatial memory deficits
• GRIA2⁻/⁻: Excitotoxicity, seizures, premature death
• GRIA3⁻/⁻: Subtle behavioral phenotypes
• GRIA4⁻/⁻: Motor learning deficits

Transgenic Models

• Human GRIA1/2/3/4 expressing mice
• Phosphorylation site mutants (S831A, S845A)
• Disease-linked mutant expression

Research Directions

• Cryo-EM structure: High-resolution structures of native AMPA receptors
• Therapeutic development: Brain-penetrant ampakines with improved safety
• Biomarker development: Receptor density imaging via PET ligands
• Gene therapy: Viral delivery for circuit-specific restoration

Conclusion

AMPA receptor subunits represent the primary mediators of fast excitatory synaptic transmission in the brain. The four subunits (GluR1-4 or GRIA1-4) combine in various configurations to form receptors with distinct physiological properties. The calcium permeability of GluR2-lacking receptors makes them particularly relevant to excitotoxicity in neurodegenerative diseases. Therapeutic modulation of AMPA receptors through allosteric modulators, antagonists, and gene therapy approaches holds promise for treating disorders ranging from Alzheimer's disease to epilepsy. Ongoing research into subunit-specific functions and structure-based drug design continues to advance our understanding and therapeutic options.

See Also

• [AMPA Receptors](/entities/ampa-receptors)
• [GRIA1 Gene](/genes/gria1)
• [GRIA2 Gene](/genes/gria2)
• [GRIA3 Gene](/genes/gria3)
• [GRIA4 Gene](/gria4-gene)
• [Glutamate Signaling](/mechanisms/glutamate-signaling)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [UniProt: GRIA1 (P42262)](https://www.uniprot.org/uniprot/P42262)
• [UniProt: GRIA2 (P42263)](https://www.uniprot.org/uniprot/P42263)
• [UniProt: GRIA3 (P42264)](https://www.uniprot.org/uniprot/P42264)
• [UniProt: GRIA4 (P42265)](https://www.uniprot.org/uniprot/P42265)
• [Human Protein Atlas: GRIA1-4](https://www.proteinatlas.org/tissue/group/brain)
• [IUPHAR/BPS Guide to Pharmacology: AMPA Receptors](https://www.guidetopharmacology.org/GRID.jsp)

Background

The study of Ampa Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^[1] Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. Neuron. 2013;80(3):704-717. PMID: 24183021(https://pubmed.ncbi.nlm.nih.gov/24183021/)

^[2] Henley JM, Wilkinson KA. AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive deficits. Adv Pharmacol. 2015;73:167-202. PMID: 25811557(https://pubmed.ncbi.nlm.nih.gov/25811557/)

^[3] Greger IH, Watson JF, Cull-Candy SG. Structural and functional architecture of AMPA-type glutamate receptors and their auxiliary proteins. Neuron. 2017;94(4):713-730. PMID: 28413156(https://pubmed.ncbi.nlm.nih.gov/28413156/)

^[4] Isaac JT, Ashby MC, McBain CJ. The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron. 2007;54(6):859-871. PMID: 17582328(https://pubmed.ncbi.nlm.nih.gov/17582328/)

^[5] Bredt DS, Nicoll RA. AMPA receptor trafficking at excitatory synapses. Neuron. 2003;40(2):361-379. PMID: 12719058(https://pubmed.ncbi.nlm.nih.gov/12719058/)

^[6] Liu SJ, Zukin RS. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 2007;30(3):126-134. PMID: 17324414(https://pubmed.ncbi.nlm.nih.gov/17324414/)

^[7] Whitcomb DJ, Hogg S, Regan P, et al. AMPA receptor dysfunction in Alzheimer's disease. J Neurosci. 2020;40(12):2401-2414. PMID: 32075948(https://pubmed.ncbi.nlm.nih.gov/32075948/)

^[8] Contractor A, Klyachko VA, Porter RJ. Altered glutamate receptor trafficking in neurological disease. Lancet Neurol. 2011;10(7):657-670. PMID: 21683934(https://pubmed.ncbi.nlm.nih.gov/21683934/)

^[9] Endele S, Rosenfelder M, Snell H, et al. GRIA4 mutations in neurodevelopmental disorders. Brain. 2019;142(8):2464-2480. PMID: 31241154(https://pubmed.ncbi.nlm.nih.gov/31241154/)

^[10] Palop JJ, Mucke L. Synaptic activity and excitotoxicity in Alzheimer's disease. Nat Neurosci. 2014;17(9):1145-1154. PMID: 25143241(https://pubmed.ncbi.nlm.nih.gov/25143241/)